{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T19:53:14Z","timestamp":1783626794877,"version":"3.55.0"},"reference-count":128,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>There is a growing prevalence of pancreatic cancer, accompanied by accelerated disease progression and diminished survival rates. Radical resection with clear margins remains the sole viable option for achieving a long-term cure in patients. In cases of advanced, unresectable, and metastatic disease, chemotherapy based on leucovorin, 5-fluorouracil, irinotecan, oxaliplatin, gemcitabine, or nab-paclitaxel represents the cornerstone of the treatment. Considering the limited treatment options available following initial therapy, the strategy of repurposing commonly prescribed drugs such as antihypertensives into anti-cancer therapies in palliative treatment represents a promising avenue for enhancing survival in patients with pancreatic ductal adenocarcinoma. The repurposing of existing drugs is typically a more cost-effective and expedient strategy than the development of new ones. The potential for antihypertensive drugs to be employed as adjunctive therapies could facilitate a more comprehensive treatment approach by targeting multiple pathways involved in cancer progression and acquired resistance to treatment. Antihypertensive medications, particularly those belonging to the pharmacological classes of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and calcium channel blockers, are commonly prescribed and have well-established safety profiles, particularly among patients with pancreatic cancer who are affected by multiple comorbidities. Therefore, we emphasize the preclinical and clinical evidence supporting the use of antihypertensive agents in the treatment of pancreatic cancer, emphasizing their beneficial chemosensitizing effects.<\/jats:p>","DOI":"10.3390\/cancers16233945","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T08:38:24Z","timestamp":1732523904000},"page":"3945","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Correlation Between Antihypertensive Drugs and Survival Among Patients with Pancreatic Ductal Adenocarcinoma"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5801-5913","authenticated-orcid":false,"given":"Natalia","family":"Kluz","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6509-5993","authenticated-orcid":false,"given":"Leszek","family":"Kraj","sequence":"additional","affiliation":[{"name":"Department of Oncology, Medical University of Warsaw, 02-091 Warsaw, Poland"},{"name":"Department of Molecular Biology, Institute of Genetics and Animal Biotechnology, Polish Academy of Sciences, 05-552 Garbatka, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2608-5319","authenticated-orcid":false,"given":"Paulina","family":"Chmiel","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology, Institute of Genetics and Animal Biotechnology, Polish Academy of Sciences, 05-552 Garbatka, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5851-2856","authenticated-orcid":false,"given":"Adam M.","family":"Przyby\u0142kowski","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Internal Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucjan","family":"Wyrwicz","sequence":"additional","affiliation":[{"name":"Department of Oncology and Radiotherapy, Maria Sklodowska-Curie National Cancer Research Institute, 02-781 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafa\u0142","family":"Stec","sequence":"additional","affiliation":[{"name":"Department of Oncology, Medical University of Warsaw, 02-091 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0148-541X","authenticated-orcid":false,"given":"\u0141ukasz","family":"Szyma\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Molecular Biology, Institute of Genetics and Animal Biotechnology, Polish Academy of Sciences, 05-552 Garbatka, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1245\/s10434-020-09543-x","article-title":"Clinical Implication of Node-negative Resectable Pancreatic Cancer","volume":"28","author":"Yamada","year":"2021","journal-title":"Ann. Surg. Oncol."},{"key":"ref_2","unstructured":"(2024, July 26). Available online: https:\/\/www.esmo.org\/guidelines\/guidelines-by-topic\/gastrointestinal-cancers\/pancreatic-cancer."},{"key":"ref_3","unstructured":"(2024, July 26). Available online: https:\/\/old-prod.asco.org\/sites\/new-www.asco.org\/files\/content-files\/advocacy-and-policy\/documents\/2020-Metastatic-Pancreatic-Cancer-Summary-Table.pdf."},{"key":"ref_4","unstructured":"(2024, July 27). Available online: https:\/\/www.nice.org.uk\/guidance\/ng85."},{"key":"ref_5","unstructured":"(2024, July 28). Available online: https:\/\/seom.org\/images\/SEOM_CLINICAL_GUIDELINE_PANCREATIC_AND_BILIARY_TRACT_CANCER_2020.pdf."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine","volume":"369","author":"Ervin","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","article-title":"NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors","volume":"108","author":"Hubner","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1126\/science.1164368","article-title":"Core signaling pathways in human pancreatic cancers revealed by global genomic analyses","volume":"321","author":"Jones","year":"2008","journal-title":"Science"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/nm.2344","article-title":"Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy","volume":"17","author":"Collisson","year":"2011","journal-title":"Nat. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"688","DOI":"10.20892\/j.issn.2095-3941.2019.0252","article-title":"The challenge of drug resistance in pancreatic ductal adenocarcinoma: A current overview","volume":"16","author":"Mesas","year":"2019","journal-title":"Cancer Biol. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1053\/j.gastro.2021.09.022","article-title":"Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence","volume":"162","author":"Dreyer","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/ije\/dyu240","article-title":"Risk factors for pancreatic cancer: A summary review of meta-analytical studies","volume":"44","author":"Maisonneuve","year":"2015","journal-title":"Int. J. Epidemiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/MPA.0000000000000251","article-title":"Population attributable risk for pancreatic cancer in Northern Italy","volume":"44","author":"Rosato","year":"2015","journal-title":"Pancreas"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1007\/s11095-008-9661-9","article-title":"Cancer is a preventable disease that requires major lifestyle changes","volume":"25","author":"Anand","year":"2008","journal-title":"Pharm. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00592-016-0893-6","article-title":"Insulin resistance is associated with the aggressiveness of pancreatic ductal carcinoma","volume":"53","author":"Dugnani","year":"2016","journal-title":"Acta Diabetol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/MPA.0000000000000392","article-title":"Risk Factors for Early-Onset and Very-Early-Onset Pancreatic Adenocarcinoma: A Pancreatic Cancer Case-Control Consortium (PanC4) Analysis","volume":"45","author":"McWilliams","year":"2016","journal-title":"Pancreas"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40170-022-00282-z","article-title":"Effects of hyperinsulinemia on pancreatic cancer development and the immune microenvironment revealed through single-cell transcriptomics","volume":"10","author":"Zhang","year":"2022","journal-title":"Cancer Metab."},{"key":"ref_18","unstructured":"National Heart, Lung and Blood Institute (2024, July 30). What Is Metabolic Syndrome?, Available online: https:\/\/www.nhlbi.nih.gov\/health\/health-topics\/topics\/ms."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1016\/j.metabol.2011.03.005","article-title":"Metabolic syndrome and pancreatic cancer risk: A case-control study in Italy and meta-analysis","volume":"60","author":"Rosato","year":"2011","journal-title":"Metabolism"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1002\/ijc.33172","article-title":"Metabolic syndrome and risk of pancreatic cancer: A population-based prospective cohort study","volume":"147","author":"Xia","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/cncr.32737","article-title":"Metabolic syndrome, metabolic components, and their relation to the risk of pancreatic cancer","volume":"126","author":"Park","year":"2020","journal-title":"Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41419-020-2675-x","article-title":"Enalapril Overcomes Chemoresistance and Potentiates Antitumor Efficacy of 5-FU in Colorectal Cancer by Suppressing Proliferation, Angiogenesis, and NF-\u03bab\/STAT3-Regulated Proteins","volume":"11","author":"Yang","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.2147\/CMAR.S228718","article-title":"Anticancer Effects of Antihypertensive L-Type Calcium Channel Blockers on Chemoresistant Lung Cancer Cells Via Autophagy and Apoptosis","volume":"12","author":"Wong","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_25","first-page":"246","article-title":"Hypertension in Patients with Cancer","volume":"104","author":"Silva","year":"2015","journal-title":"Arq. Bras. Cardiol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/1470320313496858","article-title":"The Renin-Angiotensin System Meets the Hallmarks of Cancer","volume":"16","year":"2015","journal-title":"JRAAS\u2014J. Renin-Angiotensin-Aldosterone Syst."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.18632\/aging.101249","article-title":"Repurposing ARBs as Treatments for Breast Cancer","volume":"9","author":"George","year":"2017","journal-title":"Aging"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-17-2994","article-title":"Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial","volume":"24","author":"Aung","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41575-019-0245-4","article-title":"Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer","volume":"17","author":"Buscail","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1158\/0008-5472.CAN-19-1363","article-title":"Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers","volume":"80","author":"Mukhopadhyay","year":"2020","journal-title":"Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1016\/S1470-2045(19)30795-8","article-title":"Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: A bright future","volume":"21","author":"Christenson","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ccell.2018.12.010","article-title":"Integration of Genomic and Transcriptional Features in Pancreatic Cancer Reveals Increased Cell Cycle Progression in Metastases","volume":"35","author":"Connor","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole genomes redefine the mutational landscape of pancreatic cancer","volume":"518","author":"Waddell","year":"2015","journal-title":"Nature"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"315","DOI":"10.14701\/ahbps.2021.25.3.315","article-title":"Mutations of p53 associated with pancreatic cancer and therapeutic implications","volume":"25","author":"Voutsadakis","year":"2021","journal-title":"Ann. Hepatobiliary Pancreat. Surg."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"McCubrey, J.A., Yang, L.V., Abrams, S.L., Steelman, L.S., Follo, M.Y., Cocco, L., Ratti, S., Martelli, A.M., Augello, G., and Cervello, M. (2022). Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression. Cells, 11.","DOI":"10.3390\/cells11142155"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"djv132","DOI":"10.1093\/jnci\/djv132","article-title":"Carboxylesterase 2 as a Determinant of Response to Irinotecan and Neoadjuvant FOLFIRINOX Therapy in Pancreatic Ductal Adenocarcinoma","volume":"107","author":"Capello","year":"2015","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1101\/gad.275776.115","article-title":"Genetics and biology of pancreatic ductal adenocarcinoma","volume":"30","author":"Ying","year":"2016","journal-title":"Genes. Dev."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc3106","article-title":"RAS oncogenes: Weaving a tumorigenic web","volume":"11","author":"Grabocka","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s12943-020-01153-1","article-title":"lncRNA-PLACT1 sustains activation of NF-\u03baB pathway through a positive feedback loop with I\u03baB\u03b1\/E2F1 axis in pancreatic cancer","volume":"19","author":"Ren","year":"2020","journal-title":"Mol. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"7656031","DOI":"10.1155\/2020\/7656031","article-title":"High JAK2 Protein Expression Predicts a Poor Prognosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma","volume":"2020","author":"Song","year":"2020","journal-title":"Dis. Markers"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1158\/0008-5472.CAN-15-0896","article-title":"IL17 Functions through the Novel REG3\u03b2-JAK2-STAT3 Inflammatory Pathway to Promote the Transition from Chronic Pancreatitis to Pancreatic Cancer","volume":"75","author":"Loncle","year":"2015","journal-title":"Cancer Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1158\/1535-7163.MCT-15-0309","article-title":"GSK-3\u03b2 Governs Inflammation-Induced NFATc2 Signaling Hubs to Promote Pancreatic Cancer Progression","volume":"15","author":"Baumgart","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1158\/1078-0432.CCR-14-2425","article-title":"Metabolic Dependencies in RAS-Driven Cancers","volume":"21","author":"Kimmelman","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.bpj.2017.09.008","article-title":"Phosphorylated Calmodulin Promotes PI3K Activation by Binding to the SH2 Domains","volume":"113","author":"Zhang","year":"2017","journal-title":"Biophys. J."},{"key":"ref_45","first-page":"989","article-title":"Inhibition of the phosphatidylinositol 3\u2019-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo","volume":"1","author":"Bondar","year":"2002","journal-title":"Mol. Cancer Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1158\/1078-0432.CCR-04-1510","article-title":"RNA interference demonstrates a novel role for integrin-linked kinase as a determinant of pancreatic adenocarcinoma cell gemcitabine chemoresistance","volume":"11","author":"Duxbury","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.semcancer.2017.10.007","article-title":"KRAS, YAP, and obesity in pancreatic cancer: A signaling network with multiple loops","volume":"54","author":"Eibl","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"ref_48","first-page":"777","article-title":"Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma","volume":"1","author":"Ng","year":"2002","journal-title":"Mol. Cancer Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.gendis.2015.12.004","article-title":"Wnt\/\u03b2-catenin signaling plays an ever-expanding role in stem cell self-renewal, tumorigenesis and cancer chemoresistance","volume":"3","author":"Mohammed","year":"2016","journal-title":"Genes. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.3892\/ijo.2012.1648","article-title":"Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition","volume":"41","author":"Quint","year":"2012","journal-title":"Int. J. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"172","DOI":"10.4252\/wjsc.v10.i11.172","article-title":"Pancreatic cancer stem cells: Perspectives on potential therapeutic approaches of pancreatic ductal adenocarcinoma","volume":"10","author":"Brandi","year":"2018","journal-title":"World J. Stem Cells"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.cell.2009.02.014","article-title":"STIM1 clusters and activates CRAC channels via direct binding of a cytosolic domain to Orai1","volume":"136","author":"Park","year":"2009","journal-title":"Cell"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1161\/01.RES.0000338496.95579.56","article-title":"Stim1 and Orai1 mediate CRAC currents and store-operated calcium entry important for endothelial cell proliferation","volume":"103","author":"Abdullaev","year":"2008","journal-title":"Circ. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"C993","DOI":"10.1152\/ajpcell.00325.2009","article-title":"Essential role for STIM1\/Orai1-mediated calcium influx in PDGF-induced smooth muscle migration","volume":"298","author":"Bisaillon","year":"2010","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1096\/fj.09-131128","article-title":"Evidence for STIM1- and Orai1-dependent store-operated calcium influx through ICRAC in vascular smooth muscle cells: Role in proliferation and migration","volume":"23","author":"Potier","year":"2009","journal-title":"FASEB J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"C457","DOI":"10.1152\/ajpcell.00064.2015","article-title":"STIM and Orai proteins as novel targets for cancer therapy. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis","volume":"309","author":"Vashisht","year":"2015","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1158\/0008-5472.CAN-20-2874","article-title":"STIM1 Mediates Calcium-Dependent Epigenetic Reprogramming in Pancreatic Cancer","volume":"81","author":"Kutschat","year":"2021","journal-title":"Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1016\/j.bbamcr.2014.02.012","article-title":"Orai1 and STIM1 mediate SOCE and contribute to apoptotic resistance of pancreatic adenocarcinoma","volume":"1843","author":"Kondratska","year":"2014","journal-title":"Biochim. Biophys. Acta."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/ncb3513","article-title":"The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer","volume":"19","author":"Krebs","year":"2017","journal-title":"Nat. Cell Biol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5820","DOI":"10.1158\/0008-5472.CAN-08-2819","article-title":"Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer","volume":"69","author":"Arumugam","year":"2009","journal-title":"Cancer Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s13577-015-0117-3","article-title":"Slug contributes to gemcitabine resistance through epithelial-mesenchymal transition in CD133(+) pancreatic cancer cells","volume":"28","author":"Tsukasa","year":"2015","journal-title":"Hum. Cell"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1053\/j.gastro.2016.03.040","article-title":"Mounting pressure in the microenvironment: Fluids, solids, and cells in pancreatic ductal adenocarcinoma","volume":"150","author":"DuFort","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1002\/jmri.24995","article-title":"Feasibility of magnetic resonance elastography for the pancreas at 3T","volume":"43","author":"Itoh","year":"2016","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/jid.2011.416","article-title":"Regulatory T cells stimulate B7-H1 expression in myeloid-derived suppressor cells in ret melanomas","volume":"132","author":"Fujimura","year":"2012","journal-title":"J. Investig. Dermatol."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Ribatti, D., and Pezzella, F. (2021). Overview on the different patterns of tumor vascularization. Cells, 10.","DOI":"10.3390\/cells10030639"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nature24462","article-title":"Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer","volume":"551","author":"Balachandran","year":"2017","journal-title":"Nature"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ccr.2012.01.007","article-title":"Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma","volume":"21","author":"Provenzano","year":"2012","journal-title":"Cancer Cell"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/ncb3340","article-title":"Macrophage-secreted granulin supports pancreatic cancer metastasis by inducing liver fibrosis","volume":"18","author":"Nielsen","year":"2016","journal-title":"Nat Cell Biol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/15384047.2014.1002357","article-title":"Involvement of angiotensin II type 2 receptor (AT2R) signaling in human pancreatic ductal adenocarcinoma (PDAC): A novel AT2R agonist effectively attenuates growth of PDAC grafts in mice","volume":"16","author":"Ishiguro","year":"2015","journal-title":"Cancer Biol. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Palamaris, K., Felekouras, E., and Sakellariou, S. (2021). Epithelial to Mesenchymal Transition: Key Regulator of Pancreatic Ductal Adenocarcinoma Progression and Chemoresistance. Cancers, 13.","DOI":"10.3390\/cancers13215532"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.12998\/wjcc.v9.i19.4998","article-title":"Role of epithelial-mesenchymal transition in chemoresistance in pancreatic ductal adenocarcinoma","volume":"9","author":"Hu","year":"2021","journal-title":"World J. Clin. Cases"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1158\/1078-0432.CCR-09-0414","article-title":"Decreased blood flow with increased metabolic activity: A novel sign of pancreatic tumor aggressiveness","volume":"15","author":"Komar","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: The metabolic requirements of cell proliferation","volume":"324","author":"Cantley","year":"2009","journal-title":"Science"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Romero-Garcia, S., Moreno-Altamirano, M.M., Prado-Garcia, H., and S\u00e1nchez-Garc\u00eda, F.J. (2016). Lactate Contribution to the Tumor Microenvironment: Mechanisms, Effects on Immune Cells and Therapeutic Relevance. Front. Immunol., 7.","DOI":"10.3389\/fimmu.2016.00052"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1038\/oncsis.2015.50","article-title":"Hypoxia and metabolic adaptation of cancer cells","volume":"5","author":"Eales","year":"2016","journal-title":"Oncogenesis"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.radonc.2009.06.025","article-title":"Pyruvate into lactate and back: From the Warburg effect to symbiotic energy fuel exchange in cancer cells","volume":"92","author":"Feron","year":"2009","journal-title":"Radiother. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nrc2981","article-title":"Regulation of cancer cell metabolism","volume":"11","author":"Cairns","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.neo.2019.03.004","article-title":"Extracellular Acidosis Modulates the Expression of Epithelial-Mesenchymal Transition (EMT) Markers and Adhesion of Epithelial and Tumor Cells","volume":"21","author":"Riemann","year":"2019","journal-title":"Neoplasia"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10552-011-9881-x","article-title":"Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Cancer Progression and Survival: A Systematic Review","volume":"23","author":"Murray","year":"2012","journal-title":"Cancer Causes Control."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1158\/2159-8290.CD-15-1177","article-title":"Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy","volume":"6","author":"Incio","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Arnold, S.A., Rivera, L.B., Carbon, J.G., Toombs, J.E., Chang, C.L., Bradshaw, A.D., and Brekken, R.A. (2012). Losartan slows pancreatic tumor progression and extends survival of SPARC-null mice by abrogating aberrant TGF\u03b2 activation. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0031384"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1038\/sj.bjc.6605955","article-title":"Inhibition of Renin-Angiotensin System Affects Prognosis of Advanced Pancreatic Cancer Receiving Gemcitabine","volume":"103","author":"Nakai","year":"2010","journal-title":"Br. J. Cancer"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1111\/j.1349-7006.2012.02311.x","article-title":"Phase I Trial of Gemcitabine and Candesartan Combination Therapy in Normotensive Patients With Advanced Pancreatic Cancer: GECA1","volume":"103","author":"Nakai","year":"2012","journal-title":"Cancer Sci."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1007\/s10637-013-9972-5","article-title":"A Multicenter Phase II Trial of Gemcitabine and Candesartan Combination Therapy in Patients With Advanced Pancreatic Cancer: GECA2","volume":"31","author":"Nakai","year":"2013","journal-title":"Investig. New Drugs"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1001\/jamaoncol.2019.0892","article-title":"Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial","volume":"5","author":"Murphy","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1158\/1078-0432.CCR-22-1630","article-title":"Addition of Losartan to FOLFIRINOX and Chemoradiation Reduces Immunosuppression-Associated Genes, Tregs, and FOXP3+ Cancer Cells in Locally Advanced Pancreatic Cancer","volume":"29","author":"Boucher","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1038\/ncomms3516","article-title":"Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels","volume":"4","author":"Chauhan","year":"2013","journal-title":"Nat. Commun."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13046-023-02671-8","article-title":"Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo\/YAP1\/c-Jun axis","volume":"42","author":"Zhou","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"5959","DOI":"10.1158\/1078-0432.CCR-17-0256","article-title":"Use of Angiotensin System Inhibitors is Associated With Immune Activation and Longer Survival in Nonmetastatic Pancreatic Ductal Adenocarcinoma","volume":"23","author":"Liu","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e2200143119","DOI":"10.1073\/pnas.2200143119","article-title":"Calcium channel blockers potentiate gemcitabine chemotherapy in pancreatic cancer","volume":"119","author":"Principe","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"35931","DOI":"10.18632\/oncotarget.5933","article-title":"Fendiline inhibits proliferation and invasion of pancreatic cancer cells by interfering with ADAM10 activation and \u03b2-catenin signaling","volume":"6","author":"Woods","year":"2015","journal-title":"Oncotarget"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3892\/ijo.2016.3512","article-title":"Verapamil Inhibits Tumor Progression of Chemotherapyresistant Pancreatic Cancer Side Population Cells","volume":"49","author":"Zhao","year":"2016","journal-title":"Int. J. Oncol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"118518","DOI":"10.1016\/j.lfs.2020.118518","article-title":"Diltiazem potentiates the cytotoxicity of gemcitabine and 5-fluorouracil in PANC-1 human pancreatic cancer cells through inhibition of P-glycoprotein","volume":"262","author":"Kandil","year":"2020","journal-title":"Life Sci."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/CAD.0000000000000947","article-title":"Calcium channel blockers in pancreatic cancer: Increased overall survival in a retrospective cohort study","volume":"31","author":"Tingle","year":"2020","journal-title":"Anticancer. Drugs"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e15756","DOI":"10.1200\/JCO.2017.35.15_suppl.e15756","article-title":"Calcium channel blockers use and overall survival in pancreatic cancer patients receiving gemcitabine","volume":"35","author":"LKraj","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.hpb.2023.12.001","article-title":"Calcium channel blockers are associated with improved survival in pancreatic cancer patients undergoing neoadjuvant chemotherapy and resection","volume":"26","author":"Fong","year":"2024","journal-title":"HPB"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejphar.2011.04.055","article-title":"\u03b22-adrenoceptor blocker synergizes with gemcitabine to inhibit the proliferation of pancreatic cancer cells via apoptosis induction","volume":"665","author":"Shan","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"ref_99","unstructured":"National Cancer Institute (2024, July 30). What Is Cancer? 2015, Available online: https:\/\/www.cancer.gov\/about-cancer\/understanding\/what-is-cancer."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1634\/theoncologist.2012-0435","article-title":"FOLFIRINOX in locally advanced pancreatic cancer: The Massachusetts General Hospital Cancer Center experience","volume":"18","author":"Faris","year":"2013","journal-title":"Oncologist"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3109\/0284186X.2015.1004367","article-title":"Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma","volume":"54","author":"Mellon","year":"2015","journal-title":"Acta Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/jamaoncol.2018.0329","article-title":"Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial","volume":"4","author":"Murphy","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jconrel.2013.06.036","article-title":"Inhalation delivery of Telmisartan enhances intratumoral distribution of nanoparticles in lung cancer models","volume":"172","author":"Godugu","year":"2013","journal-title":"J. Control. Release"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"eaan5616","DOI":"10.1126\/scitranslmed.aan5616","article-title":"Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy","volume":"9","author":"Pinter","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"e211031","DOI":"10.1001\/jamanetworkopen.2021.1031","article-title":"National Trends in the Use of Neoadjuvant Therapy Before Cancer Surgery in the US From 2004 to 2016","volume":"4","author":"Aquina","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1177\/0300060512474128","article-title":"ERK1\/2 activity contributes to gemcitabine resistance in pancreatic cancer cells","volume":"41","author":"Zheng","year":"2013","journal-title":"J. Int. Med. Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1002\/jcp.30159","article-title":"ERK-mediated transcriptional activation of Dicer is involved in gemcitabine resistance of pancreatic cancer","volume":"236","author":"Su","year":"2021","journal-title":"J. Cell Physiol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"4328","DOI":"10.1158\/0008-5472.CAN-16-3143","article-title":"Fructose-1,6-bisphosphatase Inhibits ERK Activation and Bypasses Gemcitabine Resistance in Pancreatic Cancer by Blocking IQGAP1-MAPK Interaction","volume":"77","author":"Jin","year":"2017","journal-title":"Cancer Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.jcmgh.2020.06.009","article-title":"LLGL1 Regulates Gemcitabine Resistance by Modulating the ERK-SP1-OSMR Pathway in Pancreatic Ductal Adenocarcinoma","volume":"10","author":"Zhu","year":"2020","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"ref_110","first-page":"27","article-title":"Effect of verapamil on the expression of EGFR and NM23 in A549 human lung cancer cells","volume":"29","author":"Zhang","year":"2009","journal-title":"Anticancer. Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e026789","DOI":"10.1161\/JAHA.122.026789","article-title":"Dihydropyridine Calcium Channel Blockers and Risk of Pancreatic Cancer: A Population-Based Cohort Study","volume":"11","author":"Rouette","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/CAD.0b013e3283025b58","article-title":"Neurotransmission and cancer: Implications for prevention and therapy","volume":"19","author":"Schuller","year":"2008","journal-title":"Anticancer. Drugs"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-198400282-00002","article-title":"Alpha- and beta-adrenergic receptor subtypes properties, distribution and regulation","volume":"28","author":"Molinoff","year":"1984","journal-title":"Drugs"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jaci.2005.11.012","article-title":"Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation","volume":"117","author":"Johnson","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"S313","DOI":"10.1067\/mai.2002.129702","article-title":"Beta-Agonists and metabolism","volume":"110","author":"Philipson","year":"2002","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/1476-4598-10-146","article-title":"\u03b22-adrenoceptor blockage induces G1\/S phase arrest and apoptosis in pancreatic cancer cells via Ras\/Akt\/NF\u03baB pathway","volume":"10","author":"Zhang","year":"2011","journal-title":"Mol. Cancer"},{"key":"ref_117","first-page":"825","article-title":"Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol","volume":"22","author":"Guo","year":"2009","journal-title":"Oncol. Rep."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.pan.2016.03.005","article-title":"Chronic stress increases experimental pancreatic cancer growth, reduces survival and can be antagonised by beta-adrenergic receptor blockade","volume":"16","author":"Partecke","year":"2016","journal-title":"Pancreatology"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.3390\/cancers7030838","article-title":"Neural Regulation of Pancreatic Cancer: A Novel Target for Intervention","volume":"7","author":"Chang","year":"2015","journal-title":"Cancers"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"38539","DOI":"10.18632\/oncotarget.9533","article-title":"Diabetes mellitus stimulates pancreatic cancer growth and epithelial-mesenchymal transition-mediated metastasis via a p38 MAPK pathway","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.critrevonc.2003.10.008","article-title":"Tumour invasion and matrix metalloproteinases","volume":"49","author":"Polette","year":"2004","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"10357","DOI":"10.1158\/0008-5472.CAN-06-2496","article-title":"Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells","volume":"66","author":"Yang","year":"2006","journal-title":"Cancer Res."},{"key":"ref_123","first-page":"889","article-title":"Norepinephrine stimulates pancreatic cancer cell proliferation, migration and invasion via \u03b2-adrenergic receptor-dependent activation of P38\/MAPK pathway","volume":"59","author":"Huang","year":"2012","journal-title":"Hepatogastroenterology"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.bbi.2014.02.019","article-title":"Chronic stress accelerates pancreatic cancer growth and invasion: A critical role for beta-adrenergic signaling in the pancreatic microenvironment","volume":"40","author":"Le","year":"2014","journal-title":"Brain Behav. Immun."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/MPA.0b013e318184f50c","article-title":"Inhibition of pancreatic cancer cell proliferation by propranolol occurs through apoptosis induction: The study of beta-adrenoceptor antagonist\u2019s anticancer effect in pancreatic cancer cell","volume":"38","author":"Zhang","year":"2009","journal-title":"Pancreas"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1158\/0008-5472.CAN-17-0108","article-title":"Beta-Blocker Drug Use and Survival among Patients with Pancreatic Adenocarcinoma","volume":"77","author":"Udumyan","year":"2017","journal-title":"Cancer Res."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"e007299","DOI":"10.1136\/bmjopen-2014-007299","article-title":"Can analyses of electronic patient records be independently and externally validated? Study 2--the effect of \u03b2-adrenoceptor blocker therapy on cancer survival: A retrospective cohort study","volume":"5","author":"Springate","year":"2015","journal-title":"BMJ Open"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"4913","DOI":"10.2147\/OTT.S167422","article-title":"The effects of beta-blocker use on cancer prognosis: A meta-analysis based on 319,006 patients","volume":"11","author":"Na","year":"2018","journal-title":"Onco Targets Ther."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/23\/3945\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:38:46Z","timestamp":1760114326000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/23\/3945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":128,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["cancers16233945"],"URL":"https:\/\/doi.org\/10.3390\/cancers16233945","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,25]]}}}